Abstract:

Objective To evaluate the change of pulmonary function in advanced nonsmall cell lung cancer（NSCLC） patients treated by different chemotherapy regimens before and after chemotherapy. Methods Fiftynine patients with advanced NSCLC were divided into gemcitabine plus platinum（GP） group（n=30） or taxolbased regimen（n=29）. Pulmonary function was tested on 59 cases of advanced NSCLC patients treated by different chemotherapy regimens before and after chemotherapy and 63 normal controls.
Results Compared with control group， RV and RV／TCL were higher in NSCLC group before treatment（P＞0.05）， and the other indexes of ventilation function and diffusing capacity were significantly lower in NSCLC group（P＜0.05）. After chemotherapy， there was no significant change of ventilation function in NSCLC group except the raise of FEV1／FVC％（P＜0.05）， and the patients with advanced NSCLC had a significant reduction in diffusing capacity postchemotherapy. In GP group the ventilation function indexes had no differences before or after chemotherapy except the increase of FEV1／FVC％（P＜0.05） after chemotherapy， and the diffusing capacity decreased after chemotherapy（P＜0.05）. In taxolbased group， V25％ of small airway function increased after chemotherapy（P＜0.05）， while other indexes of ventilation function had no differences， and the diffusing capacity decreased after chemotherapy（P＜0.05）. Conclusion The pulmonary function decreases in advanced NSCLC patients with significant reduction in diffusing capacity postchemtherapy due to the pulmonary toxicity of gemcitabine and taxol. The pulmonary function should be detected preand postchemotherapy of NSCLC patients.